<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02002117</url>
  </required_header>
  <id_info>
    <org_study_id>201103039RB</org_study_id>
    <nct_id>NCT02002117</nct_id>
  </id_info>
  <brief_title>Genotyping of Non-small Cell Lung Cancer</brief_title>
  <official_title>Genotyping of Non-small Cell Lung Cancer Cells - A Study of Taiwan Lung Cancer Clinical Trial Consortium (TALCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The logical next step is to integrate molecular profiling into the care of all patients with&#xD;
      NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NSCLC is an area of oncology in which clinicians are beginning to use specific&#xD;
      tumor-associated molecular aberrations to assign and/or prioritize targeted therapies for&#xD;
      patients. At this early stage, multiple hurdles remain before molecular profiling becomes a&#xD;
      routine part of thoracic oncology practice. In particular, to develop specific targeted&#xD;
      therapies for patients whose tumors harbor rare mutations, it will be important to identify&#xD;
      appropriate candidates, design the appropriate trials, and execute the trials with adequate&#xD;
      numbers to achieve the necessary endpoints. Implementation will facilitate realization of the&#xD;
      promise of molecularly tailored therapy, which could lead to more effective treatments with&#xD;
      fewer side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>frequency of individual genotyping</measure>
    <time_frame>2 months</time_frame>
    <description>To determine the frequency of individual genotyping in cancer cells of advanced non-small cell lung cancer (NSCLC) patients who have participated or will commence the clinical trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>determine the frequency by DNA mass spectrometry</measure>
    <time_frame>2 months</time_frame>
    <description>To determine the frequency with which molecular profiling of a NSCLC patient's tumor by DNA mass spectrometry yields a target against which there is approved or investigational therapeutic regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>1 year</time_frame>
    <description>To determine the response rate according to RECIST, progression-free, and overall survival in patients with advanced NSCLC whose therapy is selected by molecular profile.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Gene Abnormality</condition>
  <arm_group>
    <arm_group_label>DNA mass spectrometry</arm_group_label>
    <description>DNA mass spectrometry</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DNA mass</intervention_name>
    <description>DNA mass spectrometry</description>
    <arm_group_label>DNA mass spectrometry</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      tissue and plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        We plan to collect 300 EGFR mutation positive samples (approximately 200 de novo, 100 after&#xD;
        treatment), 200 EGFR wild type adenocarcinoma patients and 100 other NSCLC patients in 3&#xD;
        years.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who have participated or will be participating a lung cancer clinical trial&#xD;
             that use EGFR-TKI or chemotherapy as first line or second line treatment.&#xD;
&#xD;
          2. Pathologic or cytological confirmation of non-small cell lung cancer (NSCLC) with&#xD;
             available tissue&#xD;
&#xD;
          3. Patients must understand and provide written informed consent prior to initiation of&#xD;
             any study-specific procedures&#xD;
&#xD;
          4. Have a life expectancy 3 months.&#xD;
&#xD;
          5. Have stage IV NSCLC (AJCC, 7th Edition)&#xD;
&#xD;
          6. No or one prior systemic therapy for advanced or metastatic NSCLC 6.1.Adjuvant&#xD;
             chemotherapy: The adjuvant chemotherapy (e.g. vinorelbine / cisplatin) should be&#xD;
             counted as one prior systemic therapy if the interval between the completion of&#xD;
             adjuvant chemotherapy and the documentation of recurrence within 12 months.&#xD;
&#xD;
             6.2.Maintenance therapy: The maintenance therapy (e.g. pemetrexed) following the&#xD;
             first-line systemic chemotherapy which achieved complete response, partial response,&#xD;
             or stable disease should not be counted as one prior systemic therapy if the&#xD;
             maintenance drug was used in first-line combination therapy&#xD;
&#xD;
          7. â‰¥20 years&#xD;
&#xD;
          8. ECOG performance status 0 - 2&#xD;
&#xD;
          9. If there is no available archived tissue, the subject must consent to undergo a biopsy&#xD;
             or surgical procedure to obtain tissue within 1 month prior to study entry, which may&#xD;
             or may not be part of the patient's routine care for their malignancy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior history of another malignancy (other than cured basal cell carcinoma of the skin&#xD;
             or cured in-situ carcinoma of the cervix) within 5 years of study entry.&#xD;
&#xD;
          2. Known HIV infection.&#xD;
&#xD;
          3. If subject has no archival tissue and refuse to do any biopsy or surgery for molecular&#xD;
             testing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chih-Hsin Yang, PhD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaying Bai, MSc</last_name>
      <phone>889911572423</phone>
      <email>yaying0508@ntuh.gov.tw</email>
    </contact>
    <investigator>
      <last_name>Chih-Hsin Yang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>September 9, 2013</study_first_submitted>
  <study_first_submitted_qc>November 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2013</study_first_posted>
  <last_update_submitted>July 28, 2014</last_update_submitted>
  <last_update_submitted_qc>July 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

